The C1 esterase inhibitor antigen test measures how much C1 inhibitor protein is present in the blood. It is a central test for hereditary angioedema caused by C1 inhibitor deficiency, a rare disorder that produces repeated swelling without hives. Attacks may affect the skin, abdomen, genitals, tongue, or throat. Unlike allergic swelling, these episodes are driven mainly by bradykinin and often do not improve with antihistamines, corticosteroids, or epinephrine.
A low antigen level strongly supports type I hereditary angioedema when C1 inhibitor function and C4 are also low. A normal or high antigen result does not rule out the disease because type II hereditary angioedema produces enough protein, but much of it does not work. Acquired C1 inhibitor deficiency can create a similar laboratory pattern later in life. For that reason, the antigen test should be interpreted as one part of a coordinated diagnostic panel rather than as a yes-or-no answer by itself.
- The antigen test measures C1 inhibitor quantity: It does not show whether the protein works normally.
- Low antigen plus low function usually fits type I hereditary angioedema: C4 is typically reduced as well.
- Normal or high antigen plus low function can fit type II hereditary angioedema: A functional assay is essential when symptoms are convincing.
- Adult-onset deficiency may be acquired: Low C1q, no family history, and an associated B-cell or autoimmune disorder increase concern.
- Results should usually be confirmed on a second sample: Repeat testing reduces errors from specimen handling, illness, age, or laboratory variation.
- Throat swelling is an emergency regardless of test status: Breathing difficulty, voice change, or rapidly worsening tongue swelling needs immediate treatment.
Table of Contents
- What C1 Inhibitor Antigen Measures
- Symptoms That Lead to Testing
- How the Test Is Collected
- Interpreting Antigen Results
- Laboratory Patterns in Angioedema
- Hereditary Versus Acquired Deficiency
- Confirming the Diagnosis
- After Testing and Emergency Care
What C1 Inhibitor Antigen Measures
C1 esterase inhibitor, usually shortened to C1 inhibitor or C1-INH, is a regulatory protein made mainly by the liver. It belongs to the serpin family of protease inhibitors. Its job is broader than its name suggests: it restrains enzymes in the complement, contact, clotting, and fibrinolytic systems.
The contact system is especially important in hereditary angioedema. When C1 inhibitor is missing or ineffective, plasma kallikrein activity can rise and generate too much bradykinin. Bradykinin makes small blood vessels leak fluid into surrounding tissues. The result is deep, often painful swelling rather than the itchy surface welts typical of histamine-driven allergy.
An antigen assay measures the concentration of C1 inhibitor protein. Laboratories commonly report the result in milligrams per deciliter, although ranges vary by method, age, and laboratory. Examples of adult reference intervals include approximately 19–37 mg/dL or 21–38 mg/dL. Those numbers are not interchangeable with every report; the range printed beside the result is the correct comparison.
The test cannot determine whether the measured protein is functional. This distinction explains the two classic forms of C1-inhibitor-deficient hereditary angioedema:
- HAE type I: The body produces too little C1 inhibitor. Antigen and function are low.
- HAE type II: The body produces a normal or increased amount, but the protein is defective. Antigen may be normal or high while function is low.
About most C1-inhibitor-deficient cases are type I, while a smaller proportion are type II. Both forms are usually caused by a disease-causing variant in the SERPING1 gene and are inherited in an autosomal dominant pattern. A parent with the condition has a 50% chance of passing the variant to each child, although a new variant can occur without an affected parent.
The antigen result therefore answers “how much protein is present?” The separate C1 esterase inhibitor function test answers “how well does it control its target enzymes?” Both questions are needed for reliable classification.
Symptoms That Lead to Testing
Testing is appropriate when swelling has features of bradykinin-mediated angioedema. The episodes usually develop over several hours, last two to five days without treatment, and resolve gradually. They often occur without hives, itching, or the rapid response to allergy medicines expected in histamine-mediated reactions.
Common presentations include:
- Repeated swelling of the hands, feet, face, lips, eyelids, or genitals
- Severe cramping abdominal pain, nausea, vomiting, or diarrhea caused by bowel-wall swelling
- Throat, tongue, or laryngeal swelling
- Swelling after dental work, surgery, trauma, illness, emotional stress, or hormonal changes
- A family history of similar unexplained episodes or deaths from airway swelling
- Recurrent “allergic reactions” that do not respond as expected to antihistamines and corticosteroids
A non-itchy, blotchy rash called erythema marginatum can occur before or during an attack. It may be mistaken for hives, but it is usually flat and not intensely itchy. Recognizing this difference helps avoid labeling every episode as allergy.
Abdominal attacks can be difficult to diagnose. Imaging may show temporary bowel-wall edema or abdominal fluid, and blood tests may show hemoconcentration or an elevated white-cell count. Between attacks, imaging can return to normal. Some people undergo unnecessary abdominal surgery before hereditary angioedema is recognized.
Testing is also recommended for first-degree relatives of a person with confirmed C1-inhibitor-deficient hereditary angioedema, including children. Symptoms can begin in childhood, often worsen around puberty, and vary widely within the same family. A relative who has never swelled can still carry the disorder.
The test is less likely to explain swelling that always occurs with itchy hives, responds promptly to antihistamines, or follows a clear food or environmental allergen. Even so, mixed or uncertain presentations should be assessed clinically rather than sorted by one symptom alone.
ACE inhibitor medicines can cause bradykinin-mediated angioedema with normal C1 inhibitor results. Hereditary angioedema with normal C1 inhibitor also exists and involves other genetic or still-unknown mechanisms. A normal antigen level therefore redirects the evaluation; it does not automatically prove that swelling is allergic.
How the Test Is Collected
The antigen test uses blood from a vein. Fasting is usually not required. A person can generally take routine medicines unless the ordering clinician gives different instructions, but every current drug should be disclosed because several medicines can cause or alter the evaluation of angioedema.
Unlike functional complement assays, antigen concentration is relatively stable, but collection and transport still need to follow the laboratory’s instructions. Hemolysis, severe lipemia, mislabeled specimens, or use of the wrong tube can interfere with testing. The functional C1 inhibitor sample may have stricter handling requirements than the antigen sample when both are drawn together.
Testing does not have to occur during an attack. C4 and C1 inhibitor abnormalities in established type I or II disease are often present between episodes. Drawing during symptoms may increase the chance of detecting low C4 in borderline cases, but waiting for an attack is not necessary and may delay diagnosis.
Several timing issues deserve attention:
- Infants: Complement values can be lower during the first year of life, so abnormal results may need repeat testing after age one.
- C1 inhibitor replacement: Plasma-derived or recombinant C1 inhibitor can temporarily raise antigen and function. Diagnostic samples are ideally obtained before treatment when this can be done safely.
- Fresh frozen plasma: Transfusion can supply C1 inhibitor and alter results.
- Androgen therapy: Long-term attenuated androgens may increase C1 inhibitor levels in some patients.
- Acute illness: Inflammation can affect complement proteins and complicate borderline values.
Emergency treatment should never be withheld while waiting for laboratory collection. If a person has possible laryngeal angioedema, airway management and appropriate on-demand therapy take priority over obtaining an untreated sample.
A diagnostic order commonly includes C1 inhibitor antigen, C1 inhibitor function, and complement C4. C1q is often added when symptoms began later in life and acquired deficiency is possible.
Interpreting Antigen Results
The antigen result is most meaningful when categorized as clearly low, borderline, normal, or elevated and then paired with function and C4. Many guidelines describe typical untreated HAE type I values as less than about 50% of the lower limit of normal, but laboratories report concentration rather than a universal percentage. A value just below range deserves more caution than a repeatedly very low value.
Low C1 inhibitor antigen
A low concentration can support HAE type I, but it is not specific. Other explanations include acquired C1 inhibitor deficiency, protein loss, reduced liver synthesis, consumption during an inflammatory process, recent sample or laboratory error, and age-related variation in young children.
HAE type I becomes much more likely when all of the following fit:
- Recurrent angioedema without hives
- Low C1 inhibitor antigen
- Low C1 inhibitor function
- Low C4
- A compatible family history or a confirmed SERPING1 variant
A family history is helpful but not required. A substantial minority of patients have a new disease-causing variant or an unrecognized affected relative.
Normal or high C1 inhibitor antigen
A normal concentration does not exclude HAE type II. In type II disease, defective protein may circulate in normal or increased amounts. The functional assay is the decisive laboratory measurement.
A normal antigen and normal function pattern makes classic HAE type I and II unlikely, especially if C4 is also normal on repeated testing. The clinician may then consider ACE inhibitor angioedema, hereditary angioedema with normal C1 inhibitor, idiopathic nonhistaminergic angioedema, mast-cell-mediated disease, or a non-angioedema cause of swelling.
An elevated antigen concentration is not usually a diagnosis by itself. It can occur in type II disease because dysfunctional protein is produced but not effective. It may also reflect laboratory variation or inflammation. The function result determines whether an elevated antigen value is reassuring.
Borderline results
Borderline values should be repeated rather than overinterpreted. The clinician should confirm that the patient was not recently treated with C1 inhibitor concentrate or plasma and that the functional specimen was handled correctly. Repeating all three core tests together often provides a cleaner pattern than repeating antigen alone.
Laboratory Patterns in Angioedema
The following patterns organize the most common diagnostic possibilities. They are guides, not substitutes for specialist assessment.
| Condition | C1 inhibitor antigen | C1 inhibitor function | C4 | C1q |
|---|---|---|---|---|
| HAE type I | Low | Low | Usually low | Usually normal |
| HAE type II | Normal or high | Low | Usually low | Usually normal |
| Acquired C1 inhibitor deficiency | Often low | Low | Low | Often low |
| HAE with normal C1 inhibitor | Normal | Normal | Usually normal | Normal |
| ACE inhibitor angioedema | Normal | Normal | Usually normal | Normal |
| Mast-cell-mediated angioedema | Normal | Normal | Usually normal | Normal |
C4 is useful because uncontrolled activation consumes it, but it is not perfect. Some affected people can have a normal C4, particularly between attacks or because of method and reference-range differences. A normal C4 should not end the evaluation when the history strongly suggests hereditary angioedema. Likewise, low C4 occurs in immune-complex and other complement disorders, so it does not diagnose HAE by itself.
C1q helps separate hereditary from acquired C1 inhibitor deficiency. It is usually normal in hereditary type I and II disease and often low in acquired deficiency. Exceptions occur, so age at onset, family history, associated disease, and repeat results remain important. A dedicated complement C1q test is most useful when the overall pattern points toward acquired disease.
Several findings that look persuasive can still be misleading. A single low antigen result obtained after a major illness may reflect temporary consumption rather than hereditary disease. A normal antigen result may be falsely reassuring when function was never measured. Low C4 without angioedema may come from lupus, cryoglobulinemia, immune-complex kidney disease, or another complement process. Diagnosis becomes more reliable when the symptom pattern and all related measurements point in the same direction.
The response to treatment also provides context but is not a stand-alone diagnostic test. Improvement after a bradykinin-targeted medicine can support the suspected mechanism, yet spontaneous attacks also resolve and treatment response can be difficult to judge. Failure of antihistamines is common in bradykinin-mediated swelling, but some mast-cell disorders are also resistant to standard doses. Laboratory confirmation remains important whenever type I or type II HAE is suspected.
Testing mistakes most often arise when only antigen is ordered, the functional sample is mishandled, or recent replacement therapy is overlooked. Another problem is repeating a borderline value at the same time and under the same confounding conditions. A useful repeat is collected after reviewing medications and infusions, with the laboratory alerted to the suspected diagnosis and with antigen, function, and C4 drawn together. When results remain inconsistent, sending a sample to a laboratory experienced in complement testing can help resolve method-related differences.
Hereditary Versus Acquired Deficiency
Hereditary C1 inhibitor deficiency usually begins in childhood or adolescence, although the first recognized attack can occur later. Symptoms often worsen around puberty. Affected relatives may have very different attack frequency and severity, so a mild family history does not rule it out.
Acquired C1 inhibitor deficiency usually starts in adulthood, often after age 40, without an affected family member. C1 inhibitor may be consumed or neutralized by autoantibodies. The disorder can be associated with monoclonal gammopathy, B-cell lymphoma, other lymphoproliferative disease, or autoimmune illness. Sometimes angioedema appears before the underlying condition is discovered.
Features that increase concern for acquired deficiency include:
- First swelling episodes in middle or later adulthood
- No family history across several generations
- Low C1q
- A monoclonal protein, abnormal lymphocyte findings, enlarged lymph nodes, or unexplained weight loss
- Autoimmune symptoms or known systemic disease
- Detectable anti-C1 inhibitor autoantibodies, when testing is available
The evaluation may include a complete blood count, metabolic panel, serum immunoglobulins, serum protein electrophoresis, immunofixation, free light chains, imaging, and hematology assessment. The exact workup is individualized; not every adult with low C1 inhibitor needs every test at once.
Genetic testing for SERPING1 can support hereditary disease when biochemical results are unclear, help test relatives, or distinguish a hereditary case from acquired deficiency. It is not always required when repeated antigen, function, C4, and clinical findings are classic. A negative result also does not exclude every pathogenic change because test methods have limits.
Hereditary angioedema with normal C1 inhibitor is a separate group. Some cases involve variants in genes such as F12, PLG, ANGPT1, KNG1, MYOF, or HS3ST6, while many remain genetically unexplained. It should not be diagnosed simply because a person has swelling and normal C1 inhibitor. Clinicians first exclude mast-cell-mediated angioedema, medication causes, and other mimics.
Confirming the Diagnosis
Confirmation usually requires repeated biochemical testing rather than one isolated result. A practical sequence is:
- Document the swelling pattern. Note the presence or absence of hives, duration, abdominal symptoms, airway involvement, triggers, treatment response, age at onset, and family history.
- Measure C1 inhibitor antigen, C1 inhibitor function, and C4 together. The combined pattern classifies type I and type II more accurately than antigen alone.
- Repeat abnormal or discordant results. A second sample should be obtained under stable conditions and handled according to the performing laboratory’s requirements.
- Add C1q when acquired deficiency is plausible. Adult onset, no family history, and low antigen or function make this especially relevant.
- Use genetic testing selectively. SERPING1 testing can confirm hereditary disease and guide family evaluation; broader panels may be considered for suspected HAE with normal C1 inhibitor.
- Assess associated disease when indicated. Acquired deficiency should prompt an age- and symptom-appropriate search for B-cell or autoimmune disorders.
The diagnostic label should match the evidence. “Low C1 inhibitor” is a laboratory finding, while “hereditary angioedema type I” requires a compatible clinical and biochemical pattern. Misclassification can lead to the wrong treatment, unnecessary family anxiety, or missed investigation for an acquired disorder.
Children of an affected parent should be tested early, but results obtained during infancy need careful interpretation. Testing both antigen and function and repeating after the first year of life may be advised. Genetic testing for the known family variant can sometimes provide clarity sooner.
Pregnancy does not cause hereditary angioedema, but hormonal changes can alter attack frequency. Diagnostic interpretation may also be complicated by estrogen-containing contraceptives or hormone therapy, which can worsen bradykinin-mediated swelling in susceptible people. These medicines should be discussed with the specialist; they should not be stopped abruptly without a safe alternative plan. A documented biochemical diagnosis before pregnancy or a planned procedure can make preventive and emergency decisions much easier.
A specialist experienced in angioedema can also arrange an individualized action plan. This includes access to on-demand medicine, instructions for procedures such as dental work, discussion of short- or long-term prevention, and education for school, work, or caregivers.
After Testing and Emergency Care
A confirmed diagnosis changes care even when attacks are infrequent. Every patient with hereditary angioedema should have a plan for treating attacks early and for obtaining emergency help. Modern on-demand therapies target the bradykinin pathway or replace C1 inhibitor. Treatment choice depends on age, location, availability, pregnancy status, medical history, and local approval.
Antihistamines, corticosteroids, and epinephrine are often ineffective for pure bradykinin-mediated attacks. They may still be given initially when the cause is uncertain or an allergic reaction cannot be excluded, but lack of response should raise concern for another mechanism. Epinephrine remains essential when anaphylaxis is possible.
Call emergency services immediately for:
- Trouble breathing or swallowing
- Voice change, throat tightness, or noisy breathing
- Rapidly enlarging tongue or floor-of-mouth swelling
- Faintness, confusion, blue lips, or severe respiratory distress
Airway swelling can progress unpredictably. A person with prescribed on-demand HAE medicine should use it according to the treatment plan, but treatment at home does not replace emergency evaluation for laryngeal symptoms.
For abdominal swelling without airway symptoms, contact the treating team when pain is severe, persistent, accompanied by dehydration, or different from prior attacks. Appendicitis, bowel obstruction, gallbladder disease, pregnancy complications, and other emergencies can resemble an HAE abdominal attack.
Relatives should be offered counseling and testing rather than waiting for symptoms. Patients may also benefit from carrying a diagnosis card, documenting previous effective treatments, and informing surgeons and dentists before procedures. The antigen result is the starting point for this planning only when it is combined with functional testing, complement findings, and a clinical diagnosis.
References
- The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update 2022 (Guideline)
- Angioedema 2024 (Review)
- Hereditary angioedema due to C1-inhibitor deficiency 2024 (Review)
- Acquired Angioedema Due to C1-Inhibitor Deficiency 2023 (Review)
- Hereditary Angioedema with Normal C1 Inhibitor: an Updated International Consensus Paper on Diagnosis, Pathophysiology, and Treatment 2025 (Consensus)
- C-1-Esterase Inhibitor Panel 2026 (Laboratory Test Guidance)
Disclaimer
C1 inhibitor antigen results must be interpreted with C1 inhibitor function, C4, symptoms, treatment history, age, and the performing laboratory’s range. This article is educational and does not diagnose or treat hereditary or acquired angioedema. Any tongue, throat, voice, swallowing, or breathing change requires immediate emergency care.
